New treatment strategy for triple-negative breast cancer targeting micro RNA

• Project/Area Number: 24591916
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: Nagoya City University
• Principal Investigator: TOYAMA Tatsuya 名古屋市立大学, 医学(系)研究科(研究院), 准教授 (30315882)
• Co-Investigator(Kenkyū-buntansha): YOSHIMOTO Nobuyasu 名古屋市立大学, 大学院医学研究科, 助教 (10551244)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000); Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2012: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
• Keywords: miR-210 / 乳癌

Outline of Final Research Achievements

Here, we assessed miR-210 expression in Japanese triple negative breast cancer (TNBC) and determined its clinical significance.TaqMan MicroRNA assays for miR-210 expression were performed in Japanese breast cancers. Correlations between miR-210 expression and clinicopathological factors were analyzed. The effects of several variables on survival were tested by Cox proportional hazards regression analysis. miR-210 expression in TNBCs was significantly higher than in ER-positive/HER2-negative breast cancers. Patients whose TNBCs showed low miR-210 expression experienced significantly better disease-free and overall survival than those with high miR-210 expression. Although the prognosis of patients with TNBCs is poor, Cox univariate and multivariate analyses demonstrated that a higher expression of miR-210 was an independent factor indicating a worse prognosis than for patients with low level of miR-210.